The KCNH3 antibody is a research tool designed to target the KCNH3 protein, a member of the potassium voltage-gated channel subfamily H (Eag). Encoded by the *KCNH3* gene in humans, this channel plays a role in regulating neuronal excitability and signal transduction. KCNH3. also known as Eag2. is primarily expressed in the central nervous system, with studies implicating its involvement in synaptic plasticity, neurotransmitter release, and cognitive functions. Dysregulation of KCNH3 has been linked to neurological disorders, including epilepsy and intellectual disabilities, as well as certain cancers due to its oncogenic potential in tumor cell proliferation.
KCNH3 antibodies are widely used in Western blotting (WB), immunohistochemistry (IHC), and immunofluorescence (IF) to study protein expression patterns, subcellular localization, and tissue distribution. These antibodies aid in elucidating KCNH3's physiological roles and its pathological mechanisms. Recent research also explores KCNH3 as a therapeutic target, particularly in drug-resistant cancers or neurological conditions. Validation of KCNH3 antibodies is critical, as cross-reactivity with homologous channels (e.g., KCNH1/Eag1) can occur. Researchers prioritize antibodies with high specificity, often verified via knockout controls or peptide-blocking assays. Commercial KCNH3 antibodies are typically raised in rabbits or mice, with clones validated for reproducibility across experimental models.